Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Eyenovia, Inc.
  6. News
  7. Summary
    EYEN   US30234E1047


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Eyenovia : Material Definitive Agreement (Form 8-K)

09/15/2021 | 08:12am EDT
Entry into a Material Definitive Agreement.

On September 14, 2021, Eyenovia, Inc. (the 'Company') entered into an amendment ('Amendment 1') to that certain License Agreement (the 'License Agreement'), dated as of August 10, 2020, with Arctic Vision (Hong Kong) Limited ('Arctic Vision'). Pursuant to Amendment 1, the Company granted to Arctic Vision the exclusive right to research, develop, manufacture and commercialize an additional product, MydCombi, under the License Agreement in Greater China (mainland China, Hong Kong, Macao and Taiwan) and South Korea.

In addition to payments already made or to be made to the Company under the terms of the License Agreement, Arctic Vision must pay to the Company a one-time upfront payment of $250,000 within three business days of the effective date of Amendment 1. Arctic Vision also must pay the Company up to an aggregate of $2 million in milestone payments and development costs, depending on the achievement of various development and regulatory milestones and subject to the satisfaction of certain other conditions, as well as royalties on sales.

On September 14, 2021, the Company entered into an amendment ('Amendment 2') to the Exclusive License Agreement, dated March 8, 2015, between the Company and Senju Pharmaceutical Co., Ltd. ('Senju') which excludes Greater China and South Korea from the territory in which Senju was granted an exclusive royalty-bearing license from the Company. In consideration for this exclusion, and upon and after the execution of Amendment 1 with Arctic Vision, the Company must make payments to Senju based on non-royalty license revenue and sales revenue.

The foregoing description of Amendment 1 and Amendment 2 is qualified in its entirety by reference to Amendment 1 and Amendment 2, respectively, copies of which will be filed with the Company's Quarterly Report on Form 10-Q for the period ended September 30, 2021.


Eyenovia Inc. published this content on 15 September 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 15 September 2021 12:11:05 UTC.

© Publicnow 2021
All news about EYENOVIA, INC.
09/17EYENOVIA : Arctic Vision Expand Licence Deal to Include Another Eye Drug
09/17Arctic Vision Announces Addition of Novel Mydriatic Drug Mydcombi™ to Eyenovia Commerci..
09/15EYENOVIA : Material Definitive Agreement (Form 8-K)
09/15EYENOVIA, INC. : Entry into a Material Definitive Agreement (form 8-K)
09/15Eyenovia, Inc. Enters into Amendment to Certain License Agreement with Arctic Vision (H..
08/12EYENOVIA : Management's Discussion and Analysis of Financial Condition and Results of Oper..
08/11EYENOVIA : Announced positive topline data from its Phase 3 VISION-1 study evaluating Micr..
08/11EYENOVIA, INC. : Results of Operations and Financial Condition, Other Events, Financial St..
08/11Eyenovia, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021
08/11Eyenovia Reports Second Quarter 2021 Financial Results
More news
Analyst Recommendations on EYENOVIA, INC.
More recommendations
Financials (USD)
Sales 2021 3,49 M - -
Net income 2021 -22,3 M - -
Net Debt 2021 - - -
P/E ratio 2021 -6,60x
Yield 2021 -
Capitalization 138 M 138 M -
Capi. / Sales 2021 39,4x
Capi. / Sales 2022 13,7x
Nbr of Employees 33
Free-Float 63,8%
Duration : Period :
Eyenovia, Inc. Technical Analysis Chart | EYEN | US30234E1047 | MarketScreener
Technical analysis trends EYENOVIA, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 3
Last Close Price 5,30 $
Average target price 15,67 $
Spread / Average Target 196%
EPS Revisions
Managers and Directors
Sean Ianchulev President, CEO, Director & Chief Medical Officer
John P. Gandolfo Chief Financial Officer & Secretary
Fredric N. Eshelman Chairman
Luke Clauson VP-Engineering, Research & Development
Jennifer Clasby VP-Clinical Operations & Regulatory Affairs
Sector and Competitors
1st jan.Capi. (M$)
EYENOVIA, INC.-12.54%138
JOHNSON & JOHNSON2.49%424 619
ROCHE HOLDING AG16.59%339 442
NOVO NORDISK A/S54.22%234 792
PFIZER, INC.12.71%232 621